Hikma Pharmaceuticals Plc Response to unsolicited enquiries (0144Z)

TIDMHIK

RNS Number : 0144Z

Hikma Pharmaceuticals Plc

01 March 2013

PRESS RELEASE

Response to unsolicited enquiries

London, 1 March 2013 - Following the receipt of unsolicited enquiries, Hikma Pharmaceuticals PLC ("Hikma") confirms that it is undertaking a review of strategic options for its Injectables business.

Said Darwazah, CEO of Hikma said "We have received a number of unsolicited expressions of interest in our Injectables business and will consider the best option for shareholders."

A further announcement will be made if appropriate.

----- ENDS -----

Enquiries

Hikma Pharmaceuticals PLC

Susan Ringdal, Investor Relations Director +44 (0)20 7399 2760/ 07776 477 050

Lucinda Henderson, Investor Relations Manager +44 (0)20 7399 2765/ 07818 060 211

FTI Consulting +44 (0)20 7831 3113

Ben Atwell /Julia Phillips/Jonathan Birt/Matthew Cole

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based principally in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2011, Hikma achieved revenues of $918.0 million and profit attributable to shareholders of $80.1 million.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RSPSSEFSFFDSEED

Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024